Skip to main content

Algernon Pharmaceuticals receives notice of allowance for US patent for drug Repirinast and NASH

--News Direct--

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has received a Notice of Allowance for a patent around its work on chronic kidney disease.

Moreau tells Proactive the patent, which is titled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis”, is based around its kidney disease program with the drug NP-251 or Repirinast. This is the company’s first allowance notice received from the US patent office.

Contact Details

Proactive Canada

+1 604-688-8158

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/algernon-pharmaceuticals-receives-notice-of-allowance-for-us-patent-for-drug-repirinast-and-nash-161132949

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.